Chemotherapy or Chemotherapy Plus PD-1 Antibody in RET Fusion Positive Advanced NSCLC Patitnts: the POSEIDON Trial

计划入组 70 人 · 首次发布于 2020 年 3 月 26 日

Apply Biphasic IVM for POSEIDON Group 1

计划入组 25 人 · 首次发布于 2026 年 6 月 8 日

Levels of Inflammation in People With Cardiovascular Disease (POSEIDON)

计划入组 18,198 人 · 首次发布于 2023 年 11 月 8 日

Dual CAR-T therapy (Poseida Therapeutics)

FVIII gene therapy (Poseida Therapeutics/Takeda)

Anti-cKit CAR-T therapy(Poseida Therapeutics)

Poseida Therapeutics

United States

OISHI KOSEIDO CO., LTD.

Japan

Sequana Medical Completes Alfapump Implantations in POSEIDON Study

Sequana Medical Announces Positive Outcomes from North American Pivotal Alfapump Study (POSEIDON)

FDA Approves Expansion of Patient Enrolment in Sequana Medical's POSEIDON Study for Alfapump Treatment